Identification of SLC7A5 and transferrin as key ferroptosis modulators in triple‑negative breast cancer
Oncology Letters · 22.10.2026 · 32 (6) · 1-15
DOI: 10.3892/ol.2026.15916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 22.10.2026. Verfasst von Ruidi Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Burn, Plastic and Microsurgery, The Second Affiliated Hospital of Shenyang Medical College, Shenyang, Liaoning 110034, P.R. China. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) lacks effective targeted therapies; however, ferroptosis represents a promising therapeutic vulnerability. The present study aimed to identify and functionally characterize ferroptosis-related genes that influence TNBC progression and prognosis. RNA-sequencing data and clinical information for TNBC were obtained from The Cancer Genome Atlas and FerrDB V2 databases. Subsequently, differential expression analysis, Cox regression and functional enrichment analyses were performed. The core genes solute carrier family 7 member 5 (SLC7A5) and transferrin (TF) were selected and validated in TNBC clinical samples by western blot analysis and reverse transcription-quantitative PCR in four paired tissues and 20 paired tissues, respectively. Functional assays (Cell Counting Kit-8 and Transwell assays), and the detection of ferroptosis markers [including glutathione (GSH), malondialdehyde (MDA), reactive oxygen species (ROS)] and core ferroptosis proteins [GSH peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11), TF receptor 1 (TFRC), ferritin heavy chain 1 (FTH1), acyl-CoA synthetase long-chain family member 4 (ACSL4) and 4-hydroxy-2-nonenal (4-HNE)] were conducted in both MCF-7 [estrogen receptor (ER)-positive] and MDA-MB-231 (TNBC) cells following SLC7A5 knockdown or TF overexpression. The involvement of ferroptosis was confirmed using the specific inhibitor ferrostatin-1 (Fer-1). A total of 93 ferroptosis-associated differentially expressed genes were identified in TNBC. In addition, SLC7A5 and TF were established as independent prognostic factors. High SLC7A5 mRNA expression was associated with poor prognosis [hazard ratio (HR)=1.73; P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Burn, Plastic and Microsurgery, The Second Affiliated Hospital of Shenyang Medical College, Shenyang, Liaoning 110034, P.R. China.
- Department of Burn and Plastic Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110032, P.R. China.
- Department of General Surgery, The Second Affiliated Hospital of Shenyang Medical College, Shenyang, Liaoning 110034, P.R. China.
- Department of General Surgery, The Fourth Affiliated Hospital of Liaoning University of Traditional Chinese Medicine (Liaoning Provincial Hospital of Integrated Traditional and Western Medicine), Shenyang, Liaoning 1101…
Zitieren
APA
Liu, R., Cui, X., Guo, B., Liu, Y., Lin, F., Fu, Z., & Xie, B. (2026). Identification of SLC7A5 and transferrin as key ferroptosis modulators in triple‑negative breast cancer. Oncology Letters, 32(6), 1-15. https://doi.org/10.3892/ol.2026.15916
Vancouver
Liu R, Cui X, Guo B, Liu Y, Lin F, Fu Z, et al. Identification of SLC7A5 and transferrin as key ferroptosis modulators in triple‑negative breast cancer. Oncology Letters. 2026;32(6):1-15. doi:10.3892/ol.2026.15916
BibTeX
@article{Liu2026,
author = {Liu, Ruidi and Cui, Xiao and Guo, Bingyu and Liu, Yiting and Lin, Feng and Fu, Zhiqiang and Xie, Bing},
title = {Identification of SLC7A5 and transferrin as key ferroptosis modulators in triple‑negative breast cancer},
journal = {Oncology Letters},
year = {2026},
volume = {32},
number = {6},
pages = {1--15},
doi = {10.3892/ol.2026.15916}
}
EUVIMED